PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CHMP approves Dupixent for young children with asthma

Positive news for children aged six to 11 as Dupixent offers improved asthma treatment

The Committee for Medicinal Products for Human Use (CHMP) has recommended Dupixent (dupilumab) for approval for the treatment of children aged 6 to 11-years-old with severe asthma and type 2 inflammation. The European Commission (EC) is expected to announce a final decision on the Dupixent application in the coming months.

The recommendation is based on the pivotal phase 3 trial, which showed Dupixent–added to standard of care treatment – significantly reduced severe asthma attacks and improved lung function within two weeks, in children aged 6 to 11.

Asthma is one of the most common chronic diseases in children, with 11.6% of children aged 6 to 7 years affected worldwide. The incidence of asthma is higher in children than in adults, with approximately 1 million children in the UK are receiving treatment. Up to 85% of children with asthma have type 2 inflammation and are more likely to have a higher disease burden.

Dupixent has been recommended for extended approval to treat children in this age bracket with type 2 inflammation characterised by raised blood eosinophils or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled on two maintenance therapies.

Eosinophils are white blood cells and major effector cells in the immune system. They can, however, be damaging as part of the inflammatory process of allergic disease–and eosinophil accumulation–causes symptoms in allergic asthma.

In spite of treatment with current standard-of-care inhaled corticosteroids and bronchodilators, children with type 2 inflammation may continue to experience serious symptoms such as coughing, wheezing and difficulty breathing.

Severe asthma can impact children’s developing airways and also cause life-threatening exacerbations, while uncontrolled asthma can interfere with ordinary, essential and everyday activities for children such as sleeping, attending school and playing sports.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026